Baxalta, on cusp of buyout, bags cancer drug deal with Onconova

Baxalta ($BXLT), soon to be part of Shire ($SHPG), has decided to bag its $565 million cancer partnership for Onconova Therapeutics' ($ONTX) twice-failed treatment for myelodysplastic syndrome, a rare bone marrow disorder that often develops after patients receive cancer therapy. The deal had been struck in 2012, when Baxalta was part of Baxter ($BAX), but the company has decided it no longer fits into its "strategic priorities." In January, Baxalta succumbed to Shire's $32 billion buyout offer. The deal is expected to close this summer. More from FierceBiotech

Suggested Articles

Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job. 

Johnson & Johnson is chasing giants in its play for psoriatic arthritis with Tremfya. Strong data could help the newcomer convince the FDA.

Besting AbbVie's megablockbuster Humira is no laughing matter, but now Eli Lilly's Taltz has doubled up on head-to-head wins.